Literature DB >> 305781

Effect of altered lymphocyte function on immunologic disorders in NZB/NZW mice. III. Acceleration of disease by thymosin.

J Mehta, L Knotts, C Craig, S Burkholder, C Miller, B Hahn.   

Abstract

Administration of thymosin fraction V to NZB/NZW F1 mice, an animal model for human SLE, accelerated the appearance of proteinuria and anti-nDNA antibodies, increased deposition of immunoglobulins in kidneys, and significantly shortened survivals. Although the addition of thymosin to in vitro cultures of spleen and lymph node cells from thymosin-treated mice increased DNA synthesis in response to stimulation with Con A, in vivo treatment with thymosin did not affect the Con A response. There was no effect on in vitro responses to PHA or LPS, or on IgM antibody formation to SRBC (T cell dependent) or SSS III (T cell independent) immunizations. Antibodies to thymosin or contamination of our thymosin preparations with nucleic acids could not be demonstrated. The acceleration of autoimmune disease produced by thymosin treatment could not be explained by alteration of the T and B cell functions studied.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305781     DOI: 10.1002/art.1780210204

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  3 in total

Review 1.  Autoimmune diseases: immunopathology and etiopathogenesis.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1982-09       Impact factor: 4.307

2.  Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice.

Authors:  D Israel-Biet; L H Noel; M A Bach; M Dardenne; J F Bach
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

3.  Murine lupus nephritis: effects of cyclophosphamide on circulating and tissue bound immunoreactants.

Authors:  T Cavallo; K Graves; N A Granholm
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.